Bristol Myers Squibb (CELG-RI) Free Cash Flow (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Free Cash Flow for 18 consecutive years, with $3.1 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Free Cash Flow fell 13.16% year-over-year to $3.1 billion; the TTM figure through Jun 2026 stood at $11.4 billion (down 21.53% YoY), while the FY2025 annual figure was $12.8 billion, down 7.87% from the prior year.
• Free Cash Flow rose to $3.1 billion in Q2 2026 per CELG-RI's latest filing, from $757.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $6.0 billion in Q3 2025 and bottomed at $757.0 million in Q1 2026.
• Historically, Free Cash Flow has averaged $3.1 billion across 5 years, with a median of $3.0 billion in 2022.
• On a YoY basis, Free Cash Flow climbed as much as 72.29% in 2025 and fell as far as 60.5% in 2025.
• Bristol Myers Squibb's Free Cash Flow stood at $3.0 billion in 2022, then surged by 32.5% to $3.9 billion in 2023, then advanced by 3.54% to $4.1 billion in 2024, then plunged by 60.5% to $1.6 billion in 2025, then soared by 92.52% to $3.1 billion in 2026.
• Business Quant data shows CELG-RI's Free Cash Flow at $3.1 billion in Q2 2026, $757.0 million in Q1 2026, and $1.6 billion in Q4 2025.